T-01 OPTIMIZE trial: non-inferiority of twice-daily telaprevir versus administration every 8 hours in treatment-naïve, genotype 1 HCV infected patients
Title:
T-01 OPTIMIZE trial: non-inferiority of twice-daily telaprevir versus administration every 8 hours in treatment-naïve, genotype 1 HCV infected patients
Author:
Rizzetto, M. Buti, M. Agarwal, K. Horsmans, Y. Sievert, W. Janczewska, E. Zeuzem, S. Nyberg, L. Brown Jr., R.S. Hezode, C. Parana, R. De Meyer, S. Luo, D. Witek, J.